专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019006354A1 METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION 审中-公开
公开(公告)号：WO2019006354A1
公开(公告)日：2019-01-03
申请号：PCT/US2018/040375
申请日：2018-06-29
申请人： NATIONAL JEWISH HEALTH
发明人： JACOBELLI, Jordan , THOMPSON, Scott , CHUNG, Jeffrey
IPC分类号： A61P35/02 , C07H21/00 , C07H21/04 , C12N15/09 , C12Q1/44 , C12Q1/68
CPC分类号： G01N33/57496 , A61K31/506 , A61K31/573 , A61K31/713 , A61K39/39558 , A61K45/06 , A61K2039/804 , A61P35/02 , C07K16/3069 , C07K2317/21 , C07K2317/76 , C12N15/1135 , C12N15/1138 , C12N2310/14 , C12N2320/31 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N33/57426 , G01N2333/4727 , A61K2300/00
摘要： The present invention is related to novel methods for detecting and reducing cancer cell central nervous system colonization and methods of treating subjects having cancers that colonize in the central nervous system.

2. 发明申请

WO2018114044A1 BIOMARKER PANELS FOR BRAIN INJURY COMPLICATIONS 审中-公开
公开(公告)号：WO2018114044A1
公开(公告)日：2018-06-28
申请号：PCT/EP2017/001435
申请日：2017-12-21
申请人： UNIVERSITY OF GENEVA , FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE REBECCA
发明人： SANCHEZ, Jean-Charles , MONTANER, Joan
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6896 , G01N2333/4727 , G01N2800/2871 , G01N2800/50 , G01N2800/52 , G01N2800/60
摘要： The embodiments of the invention relate to the novel use of biomarkers, combinations of biomarkers, methods of screening, methods of screening using said biomarkers and biomarker combinations, kits, assay devices and algorithms.

3. 发明申请

WO2017055248A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE 审中-公开
标题翻译：用于治疗心力衰竭的方法和药物组合物
公开(公告)号：WO2017055248A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/072920
申请日：2016-09-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) , UNIVERSITÉ DE LORRAINE , CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU) , NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET
发明人： JAISSER, Frédéric , ZANNAD, Faiez , ROSSIGNOL, Patrick , SANTAMARIA MARTINEZ, Enrique , FERNANDEZ IRIGOYEN, Joaquin , LOPEZ-ANDRES, Natalia
IPC分类号： A61K38/17 , A61P9/04
CPC分类号： A61K38/1709 , A61K31/58 , A61K31/7088 , G01N33/6893 , G01N2333/4727 , G01N2800/325 , G01N2800/52
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of heart failure. In particular, the present invention relates to a method of treating heart failure in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a RCN-3 polypeptide or nucleic acid molecule encoding thereof.
摘要翻译：本发明涉及用于治疗心力衰竭的方法和药物组合物。特别地，本发明涉及在有需要的受试者中治疗心力衰竭的方法，其包括向受试者施用治疗有效量的RCN-3多肽或其编码的核酸分子。

4. 发明申请

WO2015179125A1 TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITION OF ALLOGRAFT INFLAMMATORY FACTOR-1 审中-公开
标题翻译：通过抑制ALLOGRAFT INFLAMMATORY FACTOR-1治疗多发性硬化
公开(公告)号：WO2015179125A1
公开(公告)日：2015-11-26
申请号：PCT/US2015/029344
申请日：2015-05-06
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
发明人： SIBINGA, Nicholas, Ernst Smit , CHINNASAMY, Prameladevi , LUTZ, Sarah, E.
IPC分类号： G01N33/53 , A61K31/7105 , A61P21/00 , A61P25/00
CPC分类号： C12N15/113 , C12N2320/30 , G01N33/5047 , G01N2333/4727 , G01N2800/285
摘要： Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor- 1 (Aif-1) in a subject and for screening for such agents.
摘要翻译：公开了用于治疗多发性硬化症的方法，其包括施用减少受试者中同种异体移植物炎症因子-1（Aif-1）的表达和/或活性的试剂并筛选该试剂。

5. 发明申请

WO2015078711A3 METHODS, PEPTIDES AND ANTIBODIES FOR PREVENTING, TREATING AND DIAGNOSING AN INFLAMMATORY CONDITION 审中-公开
标题翻译：用于预防，治疗和诊断炎性病症的方法，肽和抗体
公开(公告)号：WO2015078711A3
公开(公告)日：2015-11-19
申请号：PCT/EP2014074719
申请日：2014-11-17
申请人： UNIV MUENSTER WILHELMS
发明人： ROTH JOHANNES , VOGL THOMAS
IPC分类号： A61K38/17 , C07K14/435 , C07K14/705
CPC分类号： C07K7/08 , A61K38/00 , C07K14/001 , C07K14/705 , C07K16/18 , C07K16/2896 , C07K16/44 , G01N33/68 , G01N2333/47 , G01N2333/4727 , G01N2333/70596 , G01N2500/02 , G01N2500/20
摘要： Provided is an isolated peptide or a peptidomimetic comprising a sequence corresponding to amino acid positions 431-616 or 411-616 of the human protein TLR4 or corresponding to amino acid positions 84-131 of the human protein MD-2. Provided is also an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 411 to 616 of variant 1 the human protein TLR4. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 86 to 131 of the human protein MD2. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between one of the above peptides or whole molecules and an S100A8 or S100A9 or S100A8/S100A9 protein or a functional fragment thereof.
摘要翻译：提供了分离的肽或肽模拟物，其包含对应于人蛋白质TLR4的氨基酸位置431-616或411-616或对应于人蛋白质MD-2的氨基酸位置84-131的序列。还提供了对表位具有特异性的抗体，所述表位是对应于人蛋白质TLR4的变体1的氨基酸位置411至616的区域。还提供了对表位具有特异性的抗体，所述表位是与人蛋白MD2的氨基酸位置86至131对应的区域。进一步提供这种抗体在炎性疾病的治疗或诊断中的用途。还提供了鉴定能够抑制上述肽之一或完整分子与S100A8或S100A9或S100A8 / S100A9蛋白或其功能片段之间的复合物形成的化合物的体外方法。

6. 发明申请

WO2015035452A1 BIMOLECULAR PROTEASE-BASED BIOSENSOR 审中-公开
标题翻译：基于蛋白质分解的生物传感器
公开(公告)号：WO2015035452A1
公开(公告)日：2015-03-19
申请号：PCT/AU2014/000896
申请日：2014-09-12
申请人： THE UNIVERSITY OF QUEENSLAND
发明人： STEIN, Viktor , ALEXANDROV, Kirill
IPC分类号： C12Q1/37 , G01N33/542 , C12N11/18 , C12N9/48 , C07K19/00 , C12N15/57
CPC分类号： G01N33/542 , C07K14/00 , C07K14/005 , C07K14/4728 , C07K16/00 , C07K19/00 , C07K2319/50 , C07K2319/61 , C07K2319/70 , C12N7/00 , C12N9/48 , C12N9/506 , C12N9/90 , C12N2770/34011 , C12Y304/22044 , C12Y502/01008 , G01N33/582 , G01N2333/08 , G01N2333/185 , G01N2333/4727 , G01N2333/9513
摘要： A biosensor comprises first and second molecular components and is capable of displaying protease activity in response to a binding event mediated by first and second binding partners of the biosensor. The first and second binding partners may bind each other directly or may both bind a target molecule. At least the first molecular component comprises an autoinhibited protease, whereby the binding event switches the protease frora an autoinhibited inactive state to a protease active state. The second molecular component may activate the protease of the first molecular component by binding a cross-binder which releases the autoinhibitor or by cleaving a linker which releases the autoinhibitor. The first and second molecular components may both have automhibited proteases which reciprocally activate each other.
摘要翻译：生物传感器包含第一和第二分子组分，并且能够响应由生物传感器的第一和第二结合伴侣介导的结合事件而显示蛋白酶活性。第一和第二结合配偶体可以直接结合或可以结合靶分子。至少第一分子组分包含自身抑制蛋白酶，由此结合事件将蛋白酶frora自动抑制无活性状态切换到蛋白酶活性状态。第二分子组分可以通过结合释放自身抑制剂的交叉粘合剂或通过切割释放自身抑制剂的接头来活化第一分子组分的蛋白酶。第一和第二分子组分都可以具有彼此相互激活的自身抑制的蛋白酶。

7. 发明申请

WO2014145617A2 NOVEL USES 审中-公开
标题翻译：新用途
公开(公告)号：WO2014145617A2
公开(公告)日：2014-09-18
申请号：PCT/US2014/030412
申请日：2014-03-17
申请人： INTRA-CELLULAR THERAPIES, INC.
发明人： WENNOGLE, Lawrence
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , A61K31/517 , A61K31/527 , A61K31/53 , G01N33/84 , G01N2333/4727 , G01N2800/28
摘要： The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
摘要翻译：主题通常涉及治疗和/或预防CNS疾病，障碍和/或损伤的方法。一方面，本发明涉及磷酸二酯酶1（PDE1）作为神经保护剂和/或神经再生剂的抑制剂。另一方面，该主题涉及处于CNS疾病或病症发展风险的个体。

8. 发明申请

WO2014127463A1 METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION 审中-公开
标题翻译：测量IL-6表达以测定慢性淋巴细胞白血病的风险的方法
公开(公告)号：WO2014127463A1
公开(公告)日：2014-08-28
申请号：PCT/CA2014/000139
申请日：2014-02-20
申请人： UNIVERSITY HEALTH NETWORK
发明人： KESHAVJEE, Shaf , LIU, Mingyao , CYPEL, Marcelo
IPC分类号： C12Q1/68 , G01N33/48 , G01N33/53 , G06F19/20
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/158 , G01N33/6869 , G01N2333/4727 , G01N2333/5412 , G01N2333/5428 , G01N2800/245 , G01N2800/50
摘要： Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.
摘要翻译：用于测定供体肺用于慢性同种异体移植肺功能障碍（CLAD）的方法，任选的细支气管闭塞症综合征（BOS）亚型或CLAD的限制性同种异体移植综合征（RAS）亚型或发生移植后BOS亚型或RAS亚型CLAD的风险，所述方法包括：一个。测量供体肺移植前样品中IL-6或其表达产物的RNA转录物的标准化表达水平或一种或多种S100蛋白（任选S100A8和/或S100A9）多肽表达产物的标准化表达水平在供体肺移植后的样品中; 湾基于所述IL-6，S100，任选的S100A8和/或S100A9，评估供体肺发展BOS亚型CLAD或RAS亚型CLAD的可能性，其中IL-6表达水平与增加的可能性呈正相关开发BOS移植后，S100A8表达水平与发展RAS和/或BOS亚型CLAD的可能性增加呈正相关，S100A9与具有增加的RAS亚型CLAD的可能性增加呈正相关。

9. 发明申请

WO2014068300A1 ANTI-S100A4 ANTIBODY MOLECULES AND THEIR USES 审中-公开
标题翻译： ANTI-S100A4抗体分子及其用途
公开(公告)号：WO2014068300A1
公开(公告)日：2014-05-08
申请号：PCT/GB2013/052818
申请日：2013-10-29
申请人： CANCER RESEARCH TECHNOLOGY LIMITED
发明人： KLINGENHÖFER, Jorg , AMBARTSUMIAN, Noona , GRIGORIAN, Mariam , LUKANIDIN, Eugene
IPC分类号： C07K16/18 , C07K16/30 , A61P35/00 , A61P29/00
CPC分类号： C07K16/18 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N2005/1098 , C07K16/30 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/57415 , G01N2333/4727
摘要： Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumour progression and/or in inducing tumour metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.
摘要翻译：描述了能够抑制S100A4在促进肿瘤进展和/或诱导肿瘤转移中的生物学活性的抗S100A4抗体分子。抗体分子也可用于治疗炎性病症。使用体外和体内测定来证明抗体的性质。

10. 发明申请

WO2013132347A3 IMPROVED ELISA IMMUNOASSAY FOR CALPROTECTIN 审中-公开
标题翻译：改进的ELISA免疫印迹
公开(公告)号：WO2013132347A3
公开(公告)日：2014-03-06
申请号：PCT/IB2013000886
申请日：2013-03-05
申请人： CALPRO AS , MOERK EINAR , DALE INGE , FAGERHOL MAGNE K
发明人： MOERK EINAR , DALE INGE , FAGERHOL MAGNE K
IPC分类号： G01N33/543
CPC分类号： G01N33/54306 , G01N33/577 , G01N2333/4727 , G01N2800/065
摘要： An improved immunoassay for S100A9 provides increased reproducibility and accuracy for the determination of calprotectin, allowing more accurate diagnosis and screening for inflammatory bowel disease. In particular, the immunoassay is a sandwich immunoassay that uses an unlabeled monoclonal anti-S100A9 antibody as the capture antibody and a labeled polyclonal anti-calprotectin antibody as the detection antibody. Further improvements in reproducibility and accuracy are obtained by using citrate buffer as a coating buffer to coat a solid support, such as used in an ELISA assay, with the capture antibody. In general, the method comprises the steps of: (1 ) providing a monoclonal anti-S100A9 antibody; (2) coating the monoclonal anti-S100A9 antibody onto a solid support; (c) reacting the solid support with coated monoclonal anti-S100A9 antibody with a sample that may contain calprotectin to bind any calprotectin in the sample to the solid support; (d) washing the solid support; (e) reacting the solid support with a labeled polyclonal anti-calprotectin antibody to bind the labeled polyclonal anti-calprotectin antibody to the calprotectin bound to the solid support, the labeled polyclonal antibody being able to produce a detectable signal proportional to the concentration of the antibody bound to the calprotectin bound to the solid support; and (f) measuring the detectable signal to determine the concentration of calprotectin in the sample. The invention further includes diagnostic methods, methods of screening antibodies, and kits.
摘要翻译： S100A9的改进的免疫测定提供了重新测定钙卫蛋白的重现性和准确性，允许更准确地诊断和筛选炎症性肠病。特别地，免疫测定是使用未标记的单克隆抗S100A9抗体作为捕获抗体和标记的多克隆抗钙蛋白抗体作为检测抗体的夹心免疫测定。通过使用柠檬酸盐缓冲液作为包被缓冲液，用捕获抗体涂覆固体支持物（如ELISA测定中使用的）来获得再现性和准确性的进一步改善。通常，该方法包括以下步骤：（1）提供单克隆抗S100A9抗体; （2）将单克隆抗S100A9抗体包被到固体支持物上; （c）使固体支持物与涂覆的单克隆抗S100A9抗体与可含有钙卫蛋白的样品反应以将样品中的任何钙卫蛋白结合至固体支持物; （d）洗涤固体支持物; （e）使固体支持物与标记的多克隆抗钙蛋白抗体反应，以将标记的多克隆抗钙蛋白抗体结合到与固体支持物结合的钙卫蛋白结合物上，标记的多克隆抗体能够产生与浓度为结合钙固蛋白的抗体与固体支持物结合; 和（f）测量可检测信号以确定样品中钙卫蛋白的浓度。本发明还包括诊断方法，筛选抗体的方法和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式